{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:58:15Z","timestamp":1793116695592,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.arcmed.2023.102883","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T15:51:45Z","timestamp":1694101905000},"page":"102883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-3894","authenticated-orcid":false,"given":"Ilan","family":"Shimon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2023.102883_bib0001","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.arcmed.2023.102883_bib0002","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1210\/edrv.19.3.0334","article-title":"Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice","volume":"19","author":"Bole-Feysot","year":"1998","journal-title":"Endocr Rev"},{"key":"10.1016\/j.arcmed.2023.102883_bib0003","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2023.102883_bib0004","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102883_bib0005","first-page":"316","article-title":"Current approach to treatments for prolactinomas","volume":"41","author":"Tirosh","year":"2016","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102883_bib0006","first-page":"2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102883_bib0007","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12020-015-0791-7","article-title":"Giant prolactinomas: are they really different from ordinary macroprolactinomas?","volume":"52","author":"Espinosa","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102883_bib0008","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis","volume":"105","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102883_bib0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102883_bib0010","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102883_bib0011","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102883_bib0012","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102883_bib0013","first-page":"231","article-title":"Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report","volume":"32","author":"Guastamacchia","year":"2007","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102883_bib0014","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102883_bib0015","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102883_bib0016","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000499382","article-title":"Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours","volume":"109","author":"Trouillas","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2023.102883_bib0017","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-11-0656","article-title":"Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels","volume":"166","author":"Shimazu","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102883_bib0018","article-title":"PRL-R variants are not only associated with prolactinomas but also with dopamine agonist resistance","author":"Moreira","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102883_bib0019","first-page":"568","article-title":"Normal structural dopamine type 2 receptor gene in prolactin secreting and other pituitary tumors","volume":"78","author":"Friedman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"402","key":"10.1016\/j.arcmed.2023.102883_bib0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.mce.2014.12.024","article-title":"The role of TGF-\u03b2\/Smad signaling in dopamine agonist-resistant prolactinomas","volume":"15","author":"Li","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102883_bib0021","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/jc.2011-2902","article-title":"Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs","volume":"97","author":"Peverelli","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102883_bib0022","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","article-title":"Somatic SF3B1 hotspot mutation in prolactinomas","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.arcmed.2023.102883_bib0023","doi-asserted-by":"crossref","first-page":"e1022","DOI":"10.1002\/mgg3.1022","article-title":"Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma","volume":"7","author":"Miao","year":"2019","journal-title":"Mol. Genet Genomic Med"},{"key":"10.1016\/j.arcmed.2023.102883_bib0024","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"17","key":"10.1016\/j.arcmed.2023.102883_bib0025","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.7150\/ijms.51176","article-title":"Estrogen receptor \u03b1\/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas","volume":"23","author":"Xiao","year":"2020","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.arcmed.2023.102883_bib0026","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102883_bib0027","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","article-title":"Surgery for prolactinomas: a better choice?","volume":"23","author":"Honegger","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102883_bib0028","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-16-0087","article-title":"Therapy of Endocrine Disease: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature","volume":"175","author":"Tampourlou","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102883_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220971","article-title":"Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective","author":"Mohan","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.arcmed.2023.102883_bib0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12020-022-03080-1","article-title":"Resistant prolactinomas: a case series of 26 patients","volume":"77","author":"Eshkoli","year":"2022","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.arcmed.2023.102883_bib0031","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3171\/jns.2000.93.supplement_3.0014","article-title":"Gamma knife radiosurgery for prolactinomas","volume":"93","author":"Landolt","year":"2000","journal-title":"J Neurosurg"},{"key":"10.1016\/j.arcmed.2023.102883_bib0032","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.wneu.2010.05.007","article-title":"Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas","volume":"74","author":"Tanaka","year":"2010","journal-title":"World Neurosurg"},{"key":"10.1016\/j.arcmed.2023.102883_bib0033","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1093\/ejendo\/lvad044","article-title":"Radiotherapy in aggressive or dopamine agonists resistant prolactinomas;is it still worthwhile?","volume":"188","author":"Niculescu","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102883_bib0034","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s11102-021-01165-0","article-title":"Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients","volume":"24","author":"Ceccato","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102883_bib0035","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3390\/jcm12041437","article-title":"The role of aromatase inhibitors in male prolactinoma","volume":"12","author":"Akirov","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.arcmed.2023.102883_bib0036","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2265.1986.tb01683.x","article-title":"The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201\u2013995 in patients with prolactinomas and acromegaly","volume":"25","author":"Lamberts","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102883_bib0037","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12020-018-1638-9","article-title":"Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR","volume":"61","author":"Sosa-Eroza","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102883_bib0038","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ando.2018.07.013","article-title":"Pasireotide: a potential therapeutic alternative for resistant prolactinoma","volume":"80","author":"Lasolle","year":"2019","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.arcmed.2023.102883_bib0039","doi-asserted-by":"crossref","first-page":"K21","DOI":"10.1530\/EJE-19-0279","article-title":"Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma","volume":"181","author":"Coopmans","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.arcmed.2023.102883_bib0040","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s11102-011-0373-5","article-title":"First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment","volume":"15","author":"Baldari","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102883_bib0041","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1530\/EC-19-0065","article-title":"Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/j.arcmed.2023.102883_bib0042","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102883_bib0043","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11102-023-01340-5","article-title":"The treatment of aggressive prolactinomas with everolimus","volume":"26","author":"Lin","year":"2023","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102883_bib0044","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study","volume":"187","author":"Ilie","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102883_bib0045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1530\/ERC-22-0037","article-title":"Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review","volume":"29","author":"Ilie","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2023.102883_bib0046","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12020-013-0093-x","article-title":"Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors","volume":"46","author":"Cooper","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.arcmed.2023.102883_bib0047","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","article-title":"EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas","volume":"106","author":"Cooper","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:14:16Z","timestamp":1741184056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440923001212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0188440923001212"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102883","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102883"}}